Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer

Fei, Xianming; Wang, Huan; Yuan, Wufeng; Wo, Mingyi; Jiang, Lei

doi:10.1155/2017/8983763

Cited by 36 publications

(42 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other words, cutaneous enoxaparin can shrink the tumor size and also, our results are confirmed by microscope which there was no sign of tumor at the high dose of enoxaparin. Our results were confirmed by other studies [7][8][9]. Enoxaparin in different forms has an inhibitory effect on various cancers [10][11][12][13][14][15].…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Effects of Enoxaparin Emulsion on Dimethylbenzanthracene-induced Breast Cancer in Female Rats

Bolandpayeh

Hassanpour-Ezzati

Mousavi

2018

RMM

View full text Add to dashboard Cite

Introduction: Enoxaparin is an anticoagulant medication. Anticoagulation inhibits tumor cell-mediated release of angiogenic proteins and diminishes angiogenic response. Angiogenesis is an important event in various cancers such as breast cancer. Angiogenesis provide oxygen and nutrients to tumor cells and causes tumor progression. The aim of the present study was to evaluate the anti-angiogenesis effect of an enoxaparin cream on breast cancer induced by dimethylbenzanthracene in rats. Methods: In this experimental in vivo study, 50 Wistar female rats were divided into negative control (vehicle), positive control (cream base), and 3 groups with enoxaparin treatment (40, 60, and 80 mg/ml). After one month of treatment along with breast cancer induction by dimethylbenzanthracene, breast tissue samples were isolated and stained with hematoxylin-eosin, and tumor growth suppression rate was calculated. Tumor size (length and width) was measured using a clipper, and the tumor volume was calculated using the following formula: V = (L × W × W)/2, where V is tumor volume, W is tumor width, L is tumor length. The data were analyzed using one-way ANOVA and Tukey’s post hoc test. Results: Tumor suppression was significantly increased in enoxaparin treatment groups compared to the positive control group (40 mg/ml of enoxaparin treated versus positive control group; P = 0.017, 60 mg/ml of enoxaparin treated versus positive control; P = 0.015, 40 mg/ml of enoxaparin treated versus positive control; P = 0.009, 60 mg/ml of enoxaparin treated versus 40 mg/ml of enoxaparin treated; P = 0.019, and 80 mg/ml of enoxaparin treated versus 40 mg/ml of enoxaparin treated; P = 0.011 in a dose-dependent manner. Conclusion: Enoxaparin inhibits breast cancer in a dose-dependent manner. The application of enoxaparin cream in patients with breast cancer may considerably reduce tumor growth.

show abstract

Section: Discussionsupporting

confidence: 91%

“…Breast cancer cells can become metastatic through angiogenesis [5,6]. Blood coagulation inhibitors prevent the proliferation of lung, digestive tract, and breast cancer cells [7,8]. Furthermore, heparin may have an inhibitory effect on metastasis in breast cancer cells [9].…”

Section: Introductionmentioning

confidence: 99%

Effects of Enoxaparin Emulsion on Dimethylbenzanthracene-induced Breast Cancer in Female Rats

Bolandpayeh

Hassanpour-Ezzati

Mousavi

2018

RMM

View full text Add to dashboard Cite

show abstract

“…Samples were collected and prepared as described previously [ 19 ]. In brief, venous blood of patients was collected in the morning after an overnight fast for measurements of routine hemostatic parameters including prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), thrombin time (TT), fibrinogen (FIB), D-dimer (D-D), platelet (PLT) count, and fibrinogen-D-dimer ratio (FDR) before treatment, respectively.…”

Section: Methodsmentioning

confidence: 99%

Clinical Significance of Hemostatic Parameters in the Prediction for Type 2 Diabetes Mellitus and Diabetic Nephropathy

Pan¹,

et al. 2018

Disease Markers

Self Cite

View full text Add to dashboard Cite

It would be important to predict type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN). This study was aimed at evaluating the predicting significance of hemostatic parameters for T2DM and DN. Plasma coagulation and hematologic parameters before treatment were measured in 297 T2DM patients. The risk factors and their predicting power were evaluated. T2DM patients without complications exhibited significantly different activated partial thromboplastin time (aPTT), platelet (PLT), and D-dimer (D-D) levels compared with controls (P < 0.01). Fibrinogen (FIB), PLT, and D-D increased in DN patients compared with those without complications (P < 0.001). Both aPTT and PLT were the independent risk factors for T2DM (OR: 1.320 and 1.211, P < 0.01, resp.), and FIB and PLT were the independent risk factors for DN (OR: 1.611 and 1.194, P < 0.01, resp.). The area under ROC curve (AUC) of aPTT and PLT was 0.592 and 0.647, respectively, with low sensitivity in predicting T2DM. AUC of FIB was 0.874 with high sensitivity (85%) and specificity (76%) for DN, and that of PLT was 0.564, with sensitivity (60%) and specificity (89%) based on the cutoff values of 3.15 g/L and 245 × 109/L, respectively. This study suggests that hemostatic parameters have a low predicting value for T2DM, whereas fibrinogen is a powerful predictor for DN.

show abstract

“…Furthermore, Fei et al. proved that the combination of D-dimer and tissue factor pathway inhibitor-1 (TFPI-1) measurement played an important role in predicting deep vein thrombosis (DVT) in cancer patients [27]. These researches implied that the poor prognosis of patients with elevated D-dimer level may be correlated with high incidence of venous thrombosis in cancer patients [28].…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of pretreatment D-dimer level in small-cell lung cancer: a meta-analysis

Wang

et al. 2019

Preprint

View full text Add to dashboard Cite

Purpose To determine the prognostic significance of pretreatment D-dimer level in predicting clinical outcomes, such as the overall survival (OS) and progression-free survival (PFS), of patients with small cell lung cancer (SCLC). Methods A systematic search in PubMed, Web of Science, EMBASE, Cochrane Library, CNKI, SinoMed, Wanfang and VIP databases was performed to identify available studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were applied to assess the association of pretreatment D-dimer level with prognosis of SCLC patients. All statistical analyses were conducted via the STATA 12.0 version software. Results A total of 7 studies involving 964 patients were included in this meta-analysis and all patients were from China. The results showed that elevated pretreatment D-dimer level was significantly correlated with worse OS(HR=1.90, 95% CI: 1.55-2.34, P <0.001) and PFS (HR=1.52, 95% CI: 1.24-1.85, P ＜0.001). Subgroup analyses based on the treatment, D-dimer cut-off, detection method and source of HR were also performed to further verify the prognostic value of pretreatment D-dimer level in SCLC. Conclusions Pretreatment blood concentration of D-dimer may deserve as a reliable factor to predict prognosis of Chinese patients with SCLC. More well-designed prospective studies with big samples are still needed to verify our findings.

show abstract

Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer

Cited by 36 publications

References 28 publications

Effects of Enoxaparin Emulsion on Dimethylbenzanthracene-induced Breast Cancer in Female Rats

Effects of Enoxaparin Emulsion on Dimethylbenzanthracene-induced Breast Cancer in Female Rats

Clinical Significance of Hemostatic Parameters in the Prediction for Type 2 Diabetes Mellitus and Diabetic Nephropathy

Prognostic value of pretreatment D-dimer level in small-cell lung cancer: a meta-analysis

Contact Info

Product

Resources

About